目前的治疗方案和对慢性肝胆道疾病的有前途的分子疗法
Marilena Durazzo1, Arianna Ferro1, Victor Manuel Navarro-Tableros2
1Department of Medical Sciences, University of Turin, C.so A.M. Dogliotti 14, 10126 Turin, Italy.
肝纤维化是肝硬化和癌症的前体,缺乏早期生物标志物和有效的治疗方法. 研究重点是分子途径和新疗法,为改善慢性肝病患者治疗结果提供希望.
科学领域:
- 肝病学和分子医学 肝病学和分子医学
- 胃肠病学研究 胃肠病学研究
背景情况:
- 慢性肝胆损伤驱动肝纤维化,可能导致肝硬化和肝细胞癌.
- 目前面临的挑战包括缺乏早期生物标志物和肝脏疾病的有效抗纤维菌疗法.
- 了解病原遗传机制对于开发向治疗至关重要.
研究的目的:
- 审查与代谢功能障碍相关的脂肪性肝病,病毒性肝炎 (三角形) 和自身免疫性慢性肝病中的分子变化.
- 将分子见解与当前和新兴的治疗策略联系起来.
- 突出慢性肝病前临床和临床研究的前景.
主要方法:
- 在慢性肝病中的分子机制的文献综述.
- 分析当前的分子疗法和正在进行的研究.
- 专注于代谢,病毒和自身免疫性肝脏疾病.
主要成果:
- 在关键慢性肝病中确定了详细的分子变化.
- 目前的治疗方法针对炎症,肝星细胞激活和ECM产生.
- 新的策略包括基于核酸,细胞和囊泡的疗法.
结论:
- 新兴的疗法显示出逆转慢性肝病中日益增加的发病率和死亡率的希望.
- 需要进一步的临床开发,但研究提供了重要的希望.
- 针对分子通路的有针对性的方法正在推进治疗可能性.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
